CannBioRx Life Sciences Corp (ATNFW)

Etorro trading 970x250
CannBioRx Life Sciences Corp (ATNFW) Logo

About CannBioRx Life Sciences Corp

180 Life Sciences Corp., a clinical-stage biotechnology company, focuses on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis, and pain. Its primary platform is a novel program to treat fibrosis and inflammation using anti-TNF, with its lead program in phase 2b/3 clinical trial. The company is headquatered in Menlo Park, California. Address: 830 Menlo Avenue, Menlo Park, CA, United States, 94025

CannBioRx Life Sciences Corp News and around…

Latest news about CannBioRx Life Sciences Corp (ATNFW) common stock and company :

180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio
30 Sep, 2021 Yahoo! Finance

Notice of Allowance Issued for “Method for Reducing Post-Operative Cognitive Dysfunction (POCD)”PALO ALTO, Calif., Sept. 30, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has received a Notice of Allowance, from the United States (US) Patent and Trade Office, for app

Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications
20 Sep, 2021 Yahoo! Finance

Three Anti-TNF Product Candidates To Be Included in Expected Global AgreementPALO ALTO, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that they have entered into a Memorandum of Understanding, (“MOU”) with Celltrion Healthcare, a leading biopharmaceutical c

180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement
24 Aug, 2021 Yahoo! Finance

PALO ALTO, Calif., Aug. 24, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced the closing of its previously announced private placement of 2,500,000 shares of its common stock and accompanying warrants to purchase an aggregate of up to 2,500,000 shares of common stock at a combi

180 Life Sciences Corp. Announces $15.0 Million Private Placement
19 Aug, 2021 Yahoo! Finance

PALO ALTO, Calif., Aug. 19, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that it has entered into securities purchase agreements with certain institutional investors to raise approximately $15.0 million through the private placement of 2,500,000 shares of its common stock and

Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders?
19 Aug, 2021 Yahoo! Finance

If you want to know who really controls 180 Life Sciences Corp. ( NASDAQ:ATNF ), then you'll have to look at the makeup...

Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021
02 Aug, 2021 Yahoo! Finance

The Title of his Talk Will be “From Biology to Treatment – Anti-TNF in Dupuytren’s Disease”, to be Presented During the Opening Session, “The Cutting Edge: Advancing the Science of Hand Surgery”PALO ALTO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that Ja

180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference
29 Jul, 2021 Yahoo! Finance

PALO ALTO, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that its CEO Dr. James Woody and Professor Jagdeep Nanchahal, Chairman of the Company’s Clinical Advisory Board, will be available for 1X1 meetings, and will participate in a fireside chat at the BTIG

180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue
28 Jul, 2021 Yahoo! Finance

Collaboration Between the Pioneer of Cannabis Chemistry in Israel, Professor Raphi Mechoulam, Sir Marc Feldmann’s Laboratory in Oxford, and 180 Life Sciences Scientists, Identifies a Non-Psychoactive Cannabidiol (CBD) Analogue Expected to Move Forward in Clinical Development for Inflammation and PainMENLO PARK, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development

180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1)
20 Jul, 2021 Yahoo! Finance

PALO ALTO, Calif., July 20, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it has regained Nasdaq Compliance under listing rule 5250(c)(1). As previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. (the “Company”) with the Securities and

180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2)
12 Jul, 2021 Yahoo! Finance

MENLO PARK, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that it has regained Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2). As previously disclosed in the Current Report on Form 8-K, filed by 180 Life Sciences Corp. (the “Company”) with the

180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal
07 Jul, 2021 Yahoo! Finance

PALO ALTO, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- 180 Life Sciences Corp. (NASDAQ: ATNF) (“180 Life Sciences” or the “Company”), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced today that “Collagen VI as a driver and disease biomarker in human fibrosis” has been published in the FEBS Journal as part of their State-of-the-Art Review series. Authored by Lynn Williams, Thomas Layton,

180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement
24 Feb, 2021 FinancialContent
180 Life Sciences Corp. Announces $11.7 Million Private Placement
19 Feb, 2021 FinancialContent
180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference
05 Jan, 2021 FinancialContent
180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST
03 Dec, 2020 FinancialContent
180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020
24 Nov, 2020 FinancialContent
180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants
23 Nov, 2020 FinancialContent
180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders
17 Nov, 2020 FinancialContent
180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV
10 Nov, 2020 FinancialContent

Company Now Publicly Traded on Nasdaq Under the ticker ATNF

CannBioRx Life Sciences Corp (ATNFW) is a NASDAQ Common Stock listed in

970x250